Home > Oncology > ASCO 2020 > Adjuvant pembrolizumab: durable RFS for Stage III melanoma

Adjuvant pembrolizumab: durable RFS for Stage III melanoma

At 3-years median follow-up, the randomised, phase 3 EORTC 1325/KEYNOTE-054 trial demonstrated that adjuvant pembrolizumab taken for up to 1 year in high-risk stage III melanoma patients improved recurrence-free survival (RFS), with a consistent effect across subgroups.

Prof. Alexander Eggermont (Princess Máxima Centre for Paediatric Oncology, the Netherlands) presented the study [1], whose purpose was to assess whether post-surgery therapy with pembrolizumab improves disease recurrence for high-risk participants with melanoma (Stage IIIA [> 1 mm metastasis], IIIB, and IIIC), as compared with placebo.

The EORTC 1325/KEYNOTE-054 trial included 1,019 adults with stage IIIA (15%), stage IIIB (46%), or stage IIIC (39%) resected melanoma metastatic to lymph nodes. Patients were assigned to either adjuvant pembrolizumab (200 mg every 3 weeks) for up to 1 year (n=514) or placebo (n=505) for a to...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on